Peptidergic neurotransmission enforcement restores cerebral resistance in conditions of chronic brain ischemia

Abstract

The purpose of the study was to determine the efficacy of pentoxifylline, memantine and xavron separate and combined administration in neurological and emotional disorders complex correction in rats in conditions of chronic brain ischemia. The experimental trials were performed in conditions of chronic brain ischemia in 80 male rats. Animals were observed during 7 days after carotid artery ligation. The neurological deficit and emotional behaviour were determined 1, 3, 5 and 7 days from the beginning of the trials. The efficacy of neuroprotection in case of endonasal pentoxifylline and i.p. memantine and xavron separate and combined administration was evaluated in the modeled conditions. Rats were shown to developed an expressed motor, neurological, and emotional disturbances during the post-ischemic period. Functional recovery occurred gradually within a 7-day observation period, depending on the pharmacological agent and the method of administration. Recovery of impaired functions occurred earlier (from Day 3) and more effectively when pharmacological agents were administered in combination rather than separately. The author shed that the most effective behavioral recovery was observed with combined administration of pentoxifylline with memantine and pentoxifylline with xavron. Thus, the pharmacological correction strategy targeted key pathogenetic mechanisms of chronic ischemic neuronal injury, including oxidative and ischemic pathways. The results obtained support the feasibility of using pharmacological agents with specialized routes of administration as a pathogenetically justified method of secondary neuroprotection. The author concludes that the efficacy of the developed therapeutic complex indicates the potential for treatment outcomes improvement in patients with cerebrovascular pathology. These results require further clinical verification, particularly regarding intranasal pentoxifylline administration combined with memantine or xavron.